Aprea Therapeutics, Inc. current report, 13 January 2022

Abrir documento

Aprea Therapeutics, Inc. Form 8-K Summary

Business Context and Reporting Period

Aprea Therapeutics, Inc. filed this Current Report on January 13, 2022, in connection with its participation in the 40th Annual J.P. Morgan Healthcare Conference. The filing provides a preliminary estimate of cash and cash equivalents as of December 31, 2021 and furnishes an updated corporate presentation.

Financial Position and Key Metrics

  • Cash and cash equivalents: Expected to be approximately $50.0 million to $55.0 million as of December 31, 2021.
  • The estimate is unaudited and preliminary because the 2021 consolidated financial statements had not been finalized or audited.
  • The filing does not provide clear values for revenue, net income or loss, operating cash flow, margins, debt, liquidity runway, or other financial metrics.

Material Changes Versus the Prior Comparable Period

The filing does not provide a comparison with the prior comparable period or quantify changes in cash, operating results, debt, or liquidity. Its principal disclosure is the preliminary year-end cash estimate.

Guidance, Outlook, Risks, and Unusual Items

  • Management did not provide formal financial guidance in the filing.
  • The $50.0 million to $55.0 million cash estimate may change materially following completion and audit of the 2021 financial statements.
  • Investors are cautioned not to place undue reliance on the preliminary estimate.
  • The updated corporate presentation was intended for investor meetings at the J.P. Morgan Healthcare Conference and was furnished under Regulation FD.
  • The information in Items 2.02 and 7.01, including Exhibit 99.1, was furnished rather than filed for purposes of Section 18 of the Securities Exchange Act and is not incorporated by reference except where expressly stated.

Key Facts for Investors to Verify

  1. Verify the final audited cash and cash equivalents balance for December 31, 2021.
  2. Review the subsequent annual financial statements for revenue, operating expenses, net loss, cash burn, debt, and liquidity runway.
  3. Review Exhibit 99.1 for any additional clinical, development, financing, or corporate updates presented to investors.
  4. Confirm whether the final reported cash balance differed materially from the preliminary $50.0 million to $55.0 million estimate.